Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination

Houézec, Dominique Le

doi:10.1007/s12026-014-8574-4

Cited by 22 publications

(14 citation statements)

References 33 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite this, the recombinant hepatitis B vaccine is considered one of the safest vaccines available and the evidence suggests that it does not play a role in the development of MS (29). A French paper that reported a causal link between hepatitis B vaccination and MS after the spike in MS cases following the mass vaccination in 1994-1997 was criticized for the superficial analysis of the data from the French pharmacovigilance system (30). A couple of expert panels were assembled to review the same data, but could not find such a link (31,32).…”

Section: Safety Of Vaccination In Patients With Msmentioning

confidence: 99%

Vaccination in multiple sclerosis ‑ Challenging practices (Review)

Sîrbu

Florea²,

Ghinescu

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

Infections are an ever-present problem in the medical community, even more so for patients with multiple sclerosis (MS), for whom these infections have been linked to relapses and neurological disabilities. Even though it was believed that MS can be caused by an infection, research does not support this theory. MS is a chronic inflammatory disease considered to be autoimmune. Vaccination is proven to be one of the most effective means to prevent infections, but still it is surrounded by controversy in the general populations, as well as in the MS group. Vaccines are generally considered safe for MS patients. The exceptions from this, which turn into contraindications, are a medical history of allergic reactions to one of the vaccine components and immunosuppressed patients in the particular case of live vaccines. Given the presumed autoimmunity of the disease, some medication for MS is immunosuppressive and any live vaccine should be administered before starting treatment. Although there is still confusion regarding this subject, the current guidelines have clearer recommendations about vaccinations in MS patients and especially in treated MS patients. Contents

show abstract

Section: Safety Of Vaccination In Patients With Msmentioning

confidence: 99%

Vaccination in multiple sclerosis ‑ Challenging practices (Review)

Sîrbu

Florea²,

Ghinescu

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Cet EI a en effet été évoqué dès le début de la mise en place de la vaccination par des associations de malades. Celles-ci faisaient valoir la survenue d'un grand nombre de cas de SEP après vaccination, y compris en publiant des articles pseudo-scientifiques dans des revues à comité de lecture visiblement peu regardant sur la méthodologie employée [11]. En France et en Angleterre, les premières campagnes de vaccination ont ciblé des populations de grands enfants et jeunes adultes dans les collèges et lycées.…”

Section: Vaccin Contre L'hépatite B Et Sclérose En Plaquesunclassified

Vaccins, adjuvants et réponse immunitaire post-vaccinale : bases immunologiques

Miot

Poli

Vinatier

et al. 2019

Revue Francophone des Laboratoires

View full text Add to dashboard Cite

HAL is a multidisciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

show abstract

“…For example, pursuant to the Croatian Civil Obligations Act (hereinafter: COA), 26 a person who has caused damage to another person, if he has not proven that the damage has not happen because of his fault, shall compensate for this damage. 27 However, side effects associated with the vaccine rarely appear due to negligence and most often there is no simple way to prove someone's guilt. 28 The health care professional and/ or the institution is responsible for the adverse consequences of the medical procedure when in the conduct of its employees, under principle of guilt, the existence of elements of liability are determined.…”

Section: Liability For Damagementioning

confidence: 99%

Vaccine Injury - Burden of Proof of the Defect and the Causal Link in the Light of the Judgment in the Case C-621/15

Radoja

2019

Eu and Member States – Legal and Economic Issues

View full text Add to dashboard Cite

In the European Union the liability of producers for harm caused by defective products manufactured or imported by them is regulated in Directive 85/374/EEC of 25 July 1985 on the liability for defective products. The purpose of Directive is to lay down a system of producer liability for damage caused by a defect in its product. Crucial is that it sets out a system of strict liability, so that the injured person does not have to show evidence of fault on the part of the producer. The injured person will have to prove the defect, the damage and the causal link between these. However, when it comes to the damage caused by vaccines, in case law the causal link has often been almost impossible to prove because in the scientific literature there are a number of opposing views on the risk of vaccination. Nevertheless, to the facilitation of the victims burden of proof could contribute the judgement of the Court of the European Union according to which a national court may consider that vaccination has led to the disease or damage even when there is no proof based on medical research. But, if there are other serious, specific and consistent evidence, such as the temporal proximity between the vaccination and the occurrence of a disease, the lack of personal and familiar history of that disease, together with the existence of other reported cases of the disease that occurred after such vaccines being received. Still, the Court retains caution by opposing any presumptions and warns that such cases are extremely fact-specific and require careful case-by-case considerations. In this article the author discusses the aforementioned judgement about liability for vaccine injury and its implications in the European Union.

show abstract

Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination

Cited by 22 publications

References 33 publications

Vaccination in multiple sclerosis ‑ Challenging practices (Review)

Vaccination in multiple sclerosis ‑ Challenging practices (Review)

Vaccins, adjuvants et réponse immunitaire post-vaccinale : bases immunologiques

Vaccine Injury - Burden of Proof of the Defect and the Causal Link in the Light of the Judgment in the Case C-621/15

Contact Info

Product

Resources

About